Limits...
Tong Luo Jiu Nao ameliorates Aβ1-40-induced cognitive impairment on adaptive behavior learning by modulating ERK/CaMKII/CREB signaling in the hippocampus.

Shi Z, Lu C, Sun X, Wang Q, Chen S, Li Y, Qu L, Chen L, Bu L, Liao D, Liu X - BMC Complement Altern Med (2015)

Bottom Line: Our findings first demonstrated that TLJN can improve Aβ1-40-induced amnesia in RDIL via enhancing the comprehension of action-outcome association and the utilization of cue information to guide behavior.Then, its ameliorating effects should attribute to the modulation of ERK/CaMKII/CREB signaling in the hippocampus.TLJN can markedly enhance cognitions of Aβ1-40 microinjection animal model in adaptive behavioral tasks.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences and Peking Union Medical College, Malianwa North Road No. 151, Beijing, 100193, China. zhe.shield@gmail.com.

ABSTRACT

Background: Tong Luo Jiu Nao (TLJN), a modern formula of Chinese medicine extracts on the basis of Traditional Chinese Medicine theory, has been used to treat dementia. The present study aimed to investigate its ameliorating effects on Aβ1-40-induced cognitive impairment in rats using a series of novel reward-directed instrumental learning (RDIL) tasks, and to determine its possible mechanism of action.

Methods: Rats were pretreated with TLJN extract (0.9 and 1.8 g/kg, p.o.) for 10 daysbefore surgery, and were trained to gain reward reinforcement by lever pressing at the meantime. Thereafter, rats received a bilateral microinjection of Aβ1-40 in CA1 regions of the hippocampus. Cognitive performance was evaluated with the goal directed (higher response ratio) and habit (visual signal discrimination and extinction) learning tasks, as well as on the levels of biochemical parameters and molecules.

Results: Our findings first demonstrated that TLJN can improve Aβ1-40-induced amnesia in RDIL via enhancing the comprehension of action-outcome association and the utilization of cue information to guide behavior. Then, its ameliorating effects should attribute to the modulation of ERK/CaMKII/CREB signaling in the hippocampus.

Conclusion: TLJN can markedly enhance cognitions of Aβ1-40 microinjection animal model in adaptive behavioral tasks. It has the potential, possibly as complementary and alternative therapy, to prevent and/or delay the deterioration of cognitive impairment in AD.

Show MeSH

Related in: MedlinePlus

HPLC analysis of TLJN. The concentrations of geniposide, ginsenoside and geniposidic acid were equivalent to the corresponding TLJN content, and 7.7 mg/ml TLJN contained 4.95 mg/ml, 1.02 mg/ml and 1.73 mg/ml of geniposide, ginsenoside and geniposidic acid, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4380248&req=5

Fig1: HPLC analysis of TLJN. The concentrations of geniposide, ginsenoside and geniposidic acid were equivalent to the corresponding TLJN content, and 7.7 mg/ml TLJN contained 4.95 mg/ml, 1.02 mg/ml and 1.73 mg/ml of geniposide, ginsenoside and geniposidic acid, respectively.

Mentions: The TLJN is produced by Heyi Biosciences Limited Company, Tianjin, China (Lot No: 20110321, kindly supplied by Prof. Li Pengtao in the School of Preclinical Medicine, Beijing University of Chinese Medicine). In Briefly, TLJN are extracted from Panax notoginseng and Gardenia jasminoides. The amounts of Panaxnotoginseng (5 g) and Gardenia jasminoides (8.5 g) used were based on knowledge gained from clinical practice. The preparation of TLJN was according to the procedure which has been previously described in detail [24]. The total concentration of the active components of TLJN extract was 7.7 mg/g based on data from processing and stability studies, the active ingredients of TLJN were consisted of geniposide (64.28%), geniposidic acid (13.25%) and ginsenoside Rg1 (22.47%), which were identified with a high performance liquid chromatography (HPLC) method (see Figure 1) [26].Figure 1


Tong Luo Jiu Nao ameliorates Aβ1-40-induced cognitive impairment on adaptive behavior learning by modulating ERK/CaMKII/CREB signaling in the hippocampus.

Shi Z, Lu C, Sun X, Wang Q, Chen S, Li Y, Qu L, Chen L, Bu L, Liao D, Liu X - BMC Complement Altern Med (2015)

HPLC analysis of TLJN. The concentrations of geniposide, ginsenoside and geniposidic acid were equivalent to the corresponding TLJN content, and 7.7 mg/ml TLJN contained 4.95 mg/ml, 1.02 mg/ml and 1.73 mg/ml of geniposide, ginsenoside and geniposidic acid, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4380248&req=5

Fig1: HPLC analysis of TLJN. The concentrations of geniposide, ginsenoside and geniposidic acid were equivalent to the corresponding TLJN content, and 7.7 mg/ml TLJN contained 4.95 mg/ml, 1.02 mg/ml and 1.73 mg/ml of geniposide, ginsenoside and geniposidic acid, respectively.
Mentions: The TLJN is produced by Heyi Biosciences Limited Company, Tianjin, China (Lot No: 20110321, kindly supplied by Prof. Li Pengtao in the School of Preclinical Medicine, Beijing University of Chinese Medicine). In Briefly, TLJN are extracted from Panax notoginseng and Gardenia jasminoides. The amounts of Panaxnotoginseng (5 g) and Gardenia jasminoides (8.5 g) used were based on knowledge gained from clinical practice. The preparation of TLJN was according to the procedure which has been previously described in detail [24]. The total concentration of the active components of TLJN extract was 7.7 mg/g based on data from processing and stability studies, the active ingredients of TLJN were consisted of geniposide (64.28%), geniposidic acid (13.25%) and ginsenoside Rg1 (22.47%), which were identified with a high performance liquid chromatography (HPLC) method (see Figure 1) [26].Figure 1

Bottom Line: Our findings first demonstrated that TLJN can improve Aβ1-40-induced amnesia in RDIL via enhancing the comprehension of action-outcome association and the utilization of cue information to guide behavior.Then, its ameliorating effects should attribute to the modulation of ERK/CaMKII/CREB signaling in the hippocampus.TLJN can markedly enhance cognitions of Aβ1-40 microinjection animal model in adaptive behavioral tasks.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences and Peking Union Medical College, Malianwa North Road No. 151, Beijing, 100193, China. zhe.shield@gmail.com.

ABSTRACT

Background: Tong Luo Jiu Nao (TLJN), a modern formula of Chinese medicine extracts on the basis of Traditional Chinese Medicine theory, has been used to treat dementia. The present study aimed to investigate its ameliorating effects on Aβ1-40-induced cognitive impairment in rats using a series of novel reward-directed instrumental learning (RDIL) tasks, and to determine its possible mechanism of action.

Methods: Rats were pretreated with TLJN extract (0.9 and 1.8 g/kg, p.o.) for 10 daysbefore surgery, and were trained to gain reward reinforcement by lever pressing at the meantime. Thereafter, rats received a bilateral microinjection of Aβ1-40 in CA1 regions of the hippocampus. Cognitive performance was evaluated with the goal directed (higher response ratio) and habit (visual signal discrimination and extinction) learning tasks, as well as on the levels of biochemical parameters and molecules.

Results: Our findings first demonstrated that TLJN can improve Aβ1-40-induced amnesia in RDIL via enhancing the comprehension of action-outcome association and the utilization of cue information to guide behavior. Then, its ameliorating effects should attribute to the modulation of ERK/CaMKII/CREB signaling in the hippocampus.

Conclusion: TLJN can markedly enhance cognitions of Aβ1-40 microinjection animal model in adaptive behavioral tasks. It has the potential, possibly as complementary and alternative therapy, to prevent and/or delay the deterioration of cognitive impairment in AD.

Show MeSH
Related in: MedlinePlus